Fosciclopirox is under clinical development by CicloMed and currently in Phase I for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According to GlobalData, Phase I drugs for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Fosciclopirox’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fosciclopirox overview

CPX-POM (Ciclopirox prodrug) is under development for the treatment of advanced solid tumors, relapsed/refractory acute myeloid leukemia (AML), muscle invasive bladder cancer, transitional cell carcinoma (urothelial cell carcinoma) and non muscle invasive bladder cancer as third line therapy. The drug candidate is administered through intravenous route.

For a complete picture of Fosciclopirox’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.